New obesity treatment framework prioritises GLP-1 medications as first-line therapy
The European Association for the Study of Obesity has released comprehensive guidance positioning semaglutide and tirzepatide as primary treatments for obesity and most complications. The framework, published in Nature Medicine, represents a paradigm shift towards complication-focused prescribing rather than weight loss alone, with recommendations based on systematic meta-analysis of randomised controlled trials.
